Ganesh Kishore, Ph.D. | CEO, Malaysian Life Sciences Capital Fund and Managing Partners, Spruce Capital Partners

Ganesh Kishore, Ph.D. | CEO, Malaysian Life Sciences Capital Fund and Managing Partners, Spruce Capital Partners

Dr. Ganesh Kishore is an entrepreneur and has co-founded three successful entities since 2002.  Two of the three entities are now parts of publicly traded entities (Tata/Rallis in India and Evolva in Switzerland) while the third business entity (Mogene LC in USA) serves both as an incubator of new ideas as well as a provider of genomic services across agriculture, health care and environment.  He serves on the board of three publicly listed entities, three privately held companies and the Advisory Board of Washington University.  He is also an advisor to multinational companies and Scientific American.

Dr. Kishore has a distinguished track record of accomplishments in biotechnology research and development and business.  He left DuPont in 2007 where he was Chief Biotechnology Officer to join Malaysian Life Science Capital Fund (MLSCF) as its CEO and later co-founded Spruce Capital Partners in 2013.

After receiving a Ph.D. in biochemistry from Indian Institute of Science, Dr. Kishore received postdoctoral training in chemistry and biology and also served as a Robert A Welch Fellow at The University of Texas at Austin. He then joined Monsanto Company as a Senior Research Biochemist, responsible for developing processes for the synthesis of Aspartame, the active ingredient of Nutrasweet and Equal.  He subsequently took leadership for discovering and developing the Roundup Ready technology and ultimately the entire agricultural technologies and biotechnology for Monsanto.  He was named a Distinguished Science Fellow, the highest honor bestowed upon scientists who have made outstanding contributions to the company but also the scientific field in general, and Assistant Chief Scientist of the company.

In 2002, Dr. Kishore joined DuPont as the Chief Technology Officer for its Agriculture and Nutrition Platform and took over the role of Chief Biotechnology Officer for the company in 2005.  During his tenure at DuPont, he guided the acquisition of several key technology companies and relationships and bolstered the biotech competence within the company.